Home > Boards > Free Zone > User's Groups > Elite Stocks

>>> Is MSCI a Buy?

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
gfp927z Member Profile
 
Followed By 63
Posts 24,189
Boards Moderated 74
Alias Born 03/22/05
160x600 placeholder
J&J Vaccine Benefits Outweigh Risks, EU Agency Says, as U.S. Cases Rise -- 3rd Update
Europe's health agency said a warning should be added to the product information of the Johnson & Johnson Covid-19 vaccine that unusual blood clots are a very rare possible side effect, but said the benefits of taking the shot outweigh the risks, even as the number of clotting cases rose slightly.
Stocks Drop After Big Rally
Apple Reveals Subscription Podcasts, Latest iPad Pro
Apple Unveils Subscription Podcasts During Spring Event; New iPad Pro Expected
Discord Ends Deal Talks With Microsoft -- Update
CRISPR Therapeutics Shares Up After Amending Vertex Collaboration Deal
Canadian National Makes $30 Billion Topping Bid for Kansas City Southern -- 5th Update
Discord Ends Deal Talks With Microsoft
Top Company News of the Day
IBM On Pace for Highest Close in Over a Year -- Data Talk
Boeing Board Extends Retirement Age for CEO David Calhoun -- 3rd Update
J&J Vaccine Benefits Outweigh Risks, EU Agency Says, as U.S. Cases Rise -- 2nd Update
J&J Remains Committed to Supplying 200 Million Vaccine Doses to EU, Norway and Iceland
Bonds Reflect Hope That U.S. Recovery Will Spread to Europe -- 2nd Update
Daily Mail Owner Files Antitrust Suit Against Google, Citing Royals Coverage -- Update
Canadian National Makes $30 Billion Topping Bid for Kansas City Southern -- 4th Update
Dow, S&P 500 on Track for Second Straight Day of Losses
Kering Beats 1Q Sales Forecasts as Gucci Returns to Growth
EU Agency Says Benefits of J&J Covid-19 Vaccine Outweigh Risks but Calls for Blood-Clot Warning -- Update
BD Recalls Specified Lots of ChloraPrep Hi-Lite Orange 26 mL Applicator
EU Agency Says Benefits of J&J Covid-19 Vaccine Outweigh Risks but Calls for Blood-Clot Warning
gfp927z   Saturday, 10/31/20 11:22:40 PM
Re: None
Post # of 20 
>>> Is MSCI a Buy?

The company leverages its knowledge and expertise to provide exceptional products to the financial industry while growing its subscription-based revenues year after year.


Motley Fool

by Courtney Carlsen

Sep 11, 2020


https://www.fool.com/investing/2020/09/11/is-msci-a-buy/


MSCI (NYSE:MSCI) provides investment products and financial data to some of the largest asset managers in the world. You might be more familiar with it for its exchange-traded funds (ETFs) than for its own business. But its business is a strong one, and it's been a big winner for investors, up almost 500% over the past five years.

The company has built up years of experience in the industry and an extensive collection of historical data, proprietary equity index data, risk algorithms, and environmental, social, and governance (ESG) data, along with strong intellectual property protection on its indexes. As a result, it has been able to effectively leverage this data and expertise to continually improve the index and ETF products it provides for its clients.

MSCI capitalizes on this domain knowledge through a subscription-based revenue model. In fact, subscription-based revenues make up 74% of its $1.6 billion in total revenue since June 30, 2019. Not only that, but the company is able to keep clients satisfied, as seen by its 90%-plus retention rate over the past five years. All of these factors make MSCI a great company to consider adding to your portfolio.

ETF investing is a strength of MSCI's.

A staple in the financial community

MSCI's global reach attracts many big-name clients, most notably BlackRock. The company provides support tools and services for the global investment community including indexes, portfolio construction, and risk management analytics. MSCI's goal is to help clients understand key drivers of risk and return, which in turn help them build better portfolios.

MSCI's stock market indexes make up about 60% of the company's total business. An index can focus on a general basket of stocks, such as the S&P 500, or on investments that fit a very specific criteria such as ESG stocks. MSCI uses its expertise to continuously innovate its ETF and index products. For example, it offers indexes that target systemic style factors, including volatility, size, momentum, and value. It also offers newer indexes for clients that will track ESG companies as well as ETFs based on on-trend factors, such as smart cities, the digital economy, and other disruptive technologies.

In total, MSCI calculates 226,000 indexes daily and 12,000 indexes in real time, and serves 7,800 clients across 90 countries.

Subscription-based revenues are a key growth driver

MSCI's principal business model is to license annual, recurring subscriptions for the majority of its index, analytics, and ESG products and services for a fee due in advance of the service period. For its index segment specifically, the company sells index data subscriptions that give clients access to MSCI index-linked investment products on a contractual basis, rather than on a usage basis.

In its most recent quarterly earnings report, MSCI reported total 12-month revenue of $1.6 billion, 74% of which came from recurring subscription services. Since the end of 2015, it has seen revenues growth at a compounded annual growth rate of 10%. During that same time period, adjusted earnings per share grew even faster, at a compounded annual rate of 28%.

Recurring subscription revenues continue growing, as well. In the second quarter of this year, the company reported recurring subscription revenue of $309.9 million, a 7.2% increase over the same period last year. This increase was driven thanks to 10% growth in recurring revenue from index products and a 22.7% increase in ESG products. Subscription revenue has continued to grow despite the challenges the economy has faced with COVID-19.

A look at the competition

MSCI has a number of competitors, depending on which operating segment you're looking at. In its index segment, the company competes with S&P Dow Jones Indices -- which is jointly owned by S&P Global and the CME Group -- as well as with FTSE Russell, a subsidiary of the London Stock Exchange Group. In analytics, the company finds competition from Qontigo, BlackRock Solutions, Bloomberg Finance L.P., and FactSet Research Systems.

What sets MSCI apart from its competitors is its extensive database on global markets, proprietary equity indexes, risk algorithms, and ESG. The company relies strongly on intellectual property rights to keep many aspects of its products and services proprietary. Also, its strong relationships with its clients gives it an advantage over competitors, especially since happy clients stay with MSCI for years.

A happy client base

MSCI's retention rate, a metric that tracks the company's ability to retain its customers over time, is consistently 90% and higher over the past five years.

MSCI also continues to grow its subscription run rate. This metric provides an estimate at a particular point in time of the annualized value of the company's recurring revenues under its client contracts for the next 12 months, assuming all contracts are renewed. The subscription run rate is a key operating metric for MSCI because a change in its run rate would ultimately impact its operating revenue over time. New subscription sales have an effect of increasing the company's run rate and operating revenues over time. In the past five years, the subscription run rate has consistently grown between 7% and 10%, and its subscription run rate has actually grown over 10% in each of the past three quarters.

MSCI does a good job of maintaining clientele, a sign that its customers are clearly satisfied with its services and products. Maintaining a high retention rate is essential for its subscription-based revenue model to work.

Is MSCI a buy at today's valuation?

Investors may be concerned that MSCI is too expensive for its current share price. The company has a price-to-earnings (P/E) ratio of 56, which is much above its recent norm between 30 and 40. But its consistent sales and earnings growth and customer loyalty make a strong argument that it deserves its premium.

MSCI is a great company that continues to thrive -- even in the face of the COVID-19 pandemic -- thanks to its subscription-based business model, which makes it a steady and stable investment choice despite its high valuation.

<<<







Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences